News Sentiment

ENSC sentiment intelligence

Ensysce Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.28 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+4.8% over one week, +4.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction 4.8% Price confirming higher
Trend fit Trend inactive 4.2% over four weeks
Fair value -96.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 33
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 7
TradingView 6
TradingKey 6
Investing.com 3
ChartMill 2
MT Newswires 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 14
Analyst action 1
Balance sheet 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
TradingView Direct company coverage

Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026

Jeffrey Millard, the Chief Operating Officer of Ensysce Biosciences, has resigned from his position, with the resignation becoming effective on July 10, 2026. The reasons for his departure and details about his replacement have not been disclosed. This information is based on an

Tone
Negative 39/100
Event
Market update
Published
16 Jul 2026 03:41
Source
TradingView
Stock Titan Direct company coverage

COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10

Jeffrey Millard resigned from his position as Chief Operating Officer of Ensysce Biosciences (Nasdaq: ENSC), effective July 10, 2026. The company officially reported this material event via an 8-K filing on July 15, 2026. Ensysce Biosciences emphasizes its status as an emerging g

Tone
Negative 35/100
Event
Market update
Published
15 Jul 2026 20:41
Source
Stock Titan
The Globe and Mail Direct company coverage

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Ensysce Biosciences has received the final $5.3 million installment of a $15.1 million federal grant from the National Institutes on Drug Abuse (NIDA). This funding will advance the development of PF614-MPAR, a novel opioid with oral overdose protection that has received FDA Brea

Tone
Positive 74/100
Event
Market update
Published
15 Jul 2026 04:41
Source
The Globe and Mail
Investing.com Direct company coverage

Ensysce receives $5.3M NIDA award for opioid overdose therapy

Ensysce Biosciences, Inc. (ENSC) has been awarded $5.3 million from the National Institutes on Drug Abuse (NIDA) to advance its MPAR overdose-protection technology and lead agent PF614-MPAR, bringing total NIDA support to $15.1 million. This funding will help complete a clinical

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 15:18
Source
Investing.com
Market source Direct company coverage

Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development

Ensysce Biosciences has received the final $5.3 million installment from a multi-year National Institute on Drug Abuse (NIDA) grant, bringing the total funding to $15.1 million. This funding will support the completion of the PF614-MPAR 102 clinical study and non-clinical work re

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 14:45
Source
Market source
Stock Titan Direct company coverage

Federal funds back Ensysce opioid technology designed to limit overdose

Ensysce Biosciences (NASDAQ: ENSC) has received a $5.3 million installment from the National Institute on Drug Abuse (NIDA), completing a multi-year $15.1 million federal grant for its MPAR® overdose-protection technology and lead candidate PF614-MPAR. This funding will support t

Tone
Positive 81/100
Event
Market update
Published
14 Jul 2026 11:39
Source
Stock Titan
TradingView Direct company coverage

Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings

This page provides access to Ensysce Biosciences, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. The listed documents detail the company's earnings reports, corporate events, and investor presentations from 2017 to 2026, highlighting clinic

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 06:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC

This article provides a brief financial overview of Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its forward price-to-sales ratio. It's a snapshot from TradingView, indicating the stock's status and offering links to more detailed financial data and communit

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 06:10
Source
TradingView
Stock Titan Direct company coverage

[EFFECT] Ensysce Biosciences, Inc. SEC Filing

Ensysce Biosciences, Inc. (ENSC) announced that its S-3 Shelf Registration Statement has become effective as of June 26, 2026, at 4:30 P.M. The filing was accepted by the SEC EDGAR on June 29, 2026, at 06:05 AM. This notice indicates that the company now has a registration statem

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 10:04
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Ensysce Biosciences, Inc. – NASDAQ:ENSC

This article provides financial data for Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its price-to-book forward ratio. The content is primarily a data presentation page from TradingView, including market information and links to various financial tools and c

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 03:40
Source
TradingView
Investing.com Direct company coverage

Ensysce initiates final stage of opioid overdose protection study

Ensysce Biosciences (NASDAQ:ENSC) has begun the final stage of its PF614-MPAR-102 clinical study, evaluating its MPAR technology designed to prevent oral opioid overdose. Despite the stock's significant decline over the past year and a warning from Nasdaq regarding minimum stockh

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 22:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Ensysce initiates final stage of opioid overdose protection study By Investing.com

Ensysce Biosciences (NASDAQ: ENSC) has initiated the final stage of its PF614-MPAR-102 clinical study, evaluating its Multi-Pill Abuse Resistance (MPAR) technology designed to prevent opioid overdose. Despite a significant stock decline and cash burn, the company's technology has

Tone
Neutral 50/100
Event
Balance sheet
Published
26 Jun 2026 13:14
Source
Investing.com Nigeria
grafa.com Direct company coverage

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study

Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study. This trial is evaluating PF614-MPAR, an opioid candidate with MPAR® overdose-protection technology, for the treatment of severe pain. The study is supported by the National

Tone
Positive 73/100
Event
Market update
Published
26 Jun 2026 12:45
Source
grafa.com
Moomoo Direct company coverage

Ensysce Biosciences(ENSC) Stock Options Chain | Quotes & News

This document appears to be a stub or an incomplete article related to Ensysce Biosciences (ENSC) stock options chain, quotes, and news. Currently, it contains no substantive content beyond its title.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 12:39
Source
Moomoo
Stock Titan Direct company coverage

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study for its overdose-protection opioid candidate, PF614-MPAR. This candidate utilizes MPAR® technology designed to prevent oral overdose while providing therapeutic opioid expos

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 12:10
Source
Stock Titan
TradingView Direct company coverage

Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC)

This article provides an overview of Ensysce Biosciences, Inc. (ENSC) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about ENSC, such as its market capitalization, earnings reports, revenue,

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:10
Source
TradingView
TradingKey Direct company coverage

Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Ensysce Biosciences Inc (ENSC), highlighting its current valuation score, P/E ratio, and industry ranking. As of June 26, 2026, the company holds a valuation score of 9.51, placing it 27th out of 387 in the Biotechnology & Medical Res

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Ensysce Biosciences Inc (ENSC) stock information, including its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years but has undergone several merger-related stock splits

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Jun 2026 01:49
Source
TradingKey
TradingKey Direct company coverage

Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Ensysce Biosciences Inc (ENSC). It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents basic

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 00:49
Source
TradingKey
TradingKey Direct company coverage

Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis

Ensysce Biosciences Inc (ENSC) has a weak financial health score of 7.50 out of 388 in the Biotechnology & Medical Research industry, with average operating efficiency. The company's latest quarterly revenue decreased by 27.18% year-over-year, and its net profit saw an 82.80% yea

Tone
Negative 31/100
Event
Earnings
Published
18 Jun 2026 11:09
Source
TradingKey
TradingKey Direct company coverage

Ensysce Biosciences Inc (ENSC) Institutional Confidence

This article provides an "Institutional Confidence" score for Ensysce Biosciences Inc (ENSC) as of June 17, 2026, which remains unchanged at 3.00. It details the shareholdings and activity of several institutional investors, including Adage Capital Management, L.P. and DRW Securi

Tone
Positive 70/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey